Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Corcept Therapeutics Incorporated

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Corcept Therapeutics today and set a price target of $145.00. According t...

H.C. Wainwright Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)

Truist Financial analyst Joon Lee maintained a Buy rating on Corcept Therapeutics today. The company’s shares closed yesterday at $71.10. Lee cover...

Truist Financial Sticks to Their Buy Rating for Corcept Therapeutics (CORT)

The latest update is out from Corcept Therapeutics ( ($CORT) ). On November 4, 2025, Corcept Therapeutics announced its financial results for the t...

Market Cap	$7.90B	P/E Ratio	82.22
52W High	$117.33	52W Low	$49.00
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	11.7%	52W Position	41.4%
Overall Score	39	Value Score	25
Quality Score	--	Technical Score	54

EPS Current Est	$0.94	EPS Next Est	$1.3
EPS Growth Est	+38.3%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CORT	$77.29	+2.98%	542.89K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CORT	$77.29	+3.0%	542.89K
3
4
5
6

CORT

CORT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Corcept Therapeutics Incorporated Data in Excel

Get Corcept Therapeutics Incorporated Data in Excel